7-Iodo-1H-indole-3-carbonitrile
Open Access
Abstract
The title compound was prepared by a Friedel–Crafts acylation-oxime synthesis-decarboxylation/dehydration sequence starting from commercially available 7-iodoindole with 2-(7-iodo-1H-indol-3-yl)-2-oxoacetic acid as isolated intermediate. The structural identity of the title compound was proven by elemental analysis and spectroscopic methods (IR, NMR, EI-MS), and purity was assessed by two independent HPLC methods.Keywords
This publication has 20 references indexed in Scilit:
- A historical overview of protein kinases and their targeted small molecule inhibitorsPharmacological Research, 2015
- DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implicationsPharmacology & Therapeutics, 2015
- 25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and LimitationsMolecular Pharmacology, 2015
- Advances in kinase targeting: current clinical use and clinical trialsTrends in Pharmacological Sciences, 2014
- Human CDC2-Like Kinase 1 (CLK1): A Novel Target for Alzheimer’s DiseaseCurrent Drug Targets, 2014
- Advances in kinase inhibitionCurrent Opinion in Rheumatology, 2014
- Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritisInternational Journal of Rheumatic Diseases, 2014
- 2-tert-Butyl-5,6,7,8,9,10-hexahydrocyclohepta[b]indoleMolbank, 2011
- Identification of 2-Anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as Dual PLK1/VEGF-R2 Kinase Inhibitor Chemotypes by Structure-Based Lead GenerationJournal of Medicinal Chemistry, 2010
- Die kurze Geschichte der Proteinkinase‐Inhibitoren. Jung, kompetitiv, erfolgreichPharmazie in unserer Zeit, 2008